US REGULATORY RECORDS
- FDA API DMF records
- 1
- Active (A)
- 1
- Inactive (I)
- 0
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Esomeprazole API through FDA DMF and China CDE records. Check the free-form identity, compare reported companies and read the original registry fields before assessing a potential source.
All records in this profile are visible free. An active subscription enables search, status filters and export tools.
This Esomeprazole profile covers the S enantiomer in its free form, CAS 119141-88-7. Esomeprazole magnesium, sodium, potassium and other salts, salt hydrates, pellets and finished dosage forms are excluded. Records are selected by reported name; each filing’s CAS identity and batch specifications have not been independently verified.
Esomeprazole registry coverage: 1 FDA API DMF entries and 2 CDE API registrations selected by substance name. All Esomeprazole records in this profile fit within the free preview. A subscription adds search, status filters and CSV export tools.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording, including repeated parties. No cross-registry company-name correspondences are documented for this profile.
$19.00 per month
$149.00 per year
Billed $149.00 every year
Esomeprazole coverage: 1 FDA DMF records and 2 CDE registrations. All selected records are visible free; no additional rows are hidden in this profile.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Use the Esomeprazole registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.
Showing 0 of 0 available entries.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Inspect the Esomeprazole filing’s reported holder, original subject, submission date and activity status. The record is a starting point for dossier research; it does not establish manufacturing capability or a currently available supply.
1Active (A)
0Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Showing 1 of 1 available entries.
CHINA REGULATORY RECORDS
Inspect the Esomeprazole registration numbers, original Chinese company fields and reported review status. Expand each Esomeprazole entry to see all source columns, including unfilled cells, packaging and approval references.
1Approved or qualifying prior approval (A)
1Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Showing 2 of 2 available entries.
Esomeprazole is the S enantiomer of omeprazole, with S configuration at the sulfur atom. The free form has CAS 119141-88-7. Omeprazole is a racemate containing equal amounts of the R and S enantiomers. Magnesium and sodium salts are separate chemical entities. These reference identifiers describe the page’s scope; registry names alone do not verify the composition of every filing.
Reference identity of the free form; not an independently verified CAS assignment for each registration.
The Esomeprazole free form has the molecular formula and reference masses shown here. A shared formula or mass does not establish identical stereochemistry. Salt formation and hydration change composition; confirm the exact form, assay basis, impurity specification and relevant analytical evidence with the manufacturer.
Use these references to check Esomeprazole identity, the related racemate and the scope of regulatory records.
Compare the distinct racemic substance, CAS 73590-58-6, and its separately selected registry records.
Check the stereochemical definition of Esomeprazole before comparing reported product names.
View the free-form CAS, molecular formula, reference masses and structure.
Read how DMFs support applications and why activity status does not mean supplier approval.
This page covers the free form, CAS 119141-88-7, with S configuration at sulfur. Its molecular formula is C17H19N3O3S and reference molecular weight is 345.42 g/mol. The chemical identifiers are supported by ChEBI and KEGG; inclusion of a registration is based on its reported substance name.
No. Esomeprazole identifies the S enantiomer, whereas omeprazole is a racemate containing equal amounts of the R and S enantiomers. Their common molecular formula does not make them the same chemical entity. Use the linked omeprazole profile when researching the racemate.
No. Magnesium, sodium, potassium and other salts, including salt hydrates, are excluded from this free-form selection. Pellets and finished dosage forms are also excluded. Before comparing materials, establish the precise chemical form and request the applicable specification and analytical evidence.
The supplied Q2 2026 list contains DMF 20222, held by ALIVUS LIFE SCIENCES LTD, with subject ESOMEPRAZOLE, Type II and activity status A. Its submission date is January 31, 2007. Other matching subjects describe salts or pellets and are excluded. Type II alone does not identify a filing as a free-form API.
No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. The Esomeprazole listing does not prove supplier qualification, manufacturing-site approval, a right to reference the dossier or current availability. Check the current official record and obtain the relevant documentation for your application.
The export contains two entries named exactly 艾司奥美拉唑: Y20190009862 with status A and Y20180001696 with status I. Both report 重庆莱美隆宇药业有限公司, with the company name repeated in the latter field. Separate registration numbers remain separate records; repeated names do not establish additional suppliers.
CDE status is independent of FDA activity. A can reflect joint technical review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. These labels describe the supplied Esomeprazole snapshot and require a current official check before reliance.
All Esomeprazole records currently selected for this profile are visible in the free preview. You can also download their CSV samples. A subscription adds search, status filtering and export tools across available subscription datasets. It does not reveal additional records in this profile or provide quotations, supplier qualification or live registry monitoring.
Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.
EMBL-EBI
Defines the S configuration that distinguishes this substance from racemic omeprazole.
“S configuration at the sulfur atom”
EMBL-EBI
Extract from the definition of CHEBI:50275.
KEGG
Reports CAS 119141-88-7, formula C17H19N3O3S, molecular weight 345.42 and exact mass 345.1147 for the free form.
“Esomeprazole (INN)”
KEGG
Name reported in KEGG Drug entry D07917; identifiers and masses are taken from the same entry.
EMBL-EBI
Explains the racemic identity of the related substance and why its registrations are outside this profile.
“A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.”
EMBL-EBI
Definition in ChEBI CHEBI:7772.
U.S. Food and Drug Administration
The displayed filing comes from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.
“ESOMEPRAZOLE”
U.S. Food and Drug Administration
Exact subject of DMF 20222 in worksheet 2Q2026-EXCEL, row 19422.
U.S. Food and Drug Administration
Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; their technical contents are reviewed with applications that reference them.
U.S. Food and Drug Administration
Type II is broader than APIs, so the reported subject must also be checked.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA Type II category heading.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 export supplies the two name-selected registrations, including company fields, original status codes and unfilled cells.
“艾司奥美拉唑”
Center for Drug Evaluation, National Medical Products Administration
Exact substance name reported for Y20190009862 and Y20180001696 in the supplied CSV.
Liaoning Medical Products Administration
Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.
Use the Esomeprazole records and chemical identity references to prepare your sourcing review. Compare the original names, read each registry’s status definitions and check the official sources. Subscribe when you need search, status filtering and CSV export tools.
All records in this profile are visible free. An active subscription enables search, status filters and export tools.
Report an Esomeprazole data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.
Contact data support